Conceptus to Present at the Third Annual Lazard Life Sciences Investor Conference.MOUNTAIN VIEW, Calif. -- Conceptus Inc. (Nasdaq: CPTS CPTS Certified Penetration Testing Specialist (network security) CPTS Comptroller Squadron CPTS Computer Program Test Specifications CPTS Catastrophe Personnel Tracking System CPTS Claims Procedure Training Specialist ) developer of the Essure[R] non-incisional permanent birth control system, today announced Mark Sieczkarek, president and chief executive officer of Conceptus, will be presenting at the Third Annual Lazard Life Sciences Conference. The presentation will take place on Tuesday, November 28, 2006 at 1:00 p.m. Eastern Standard Time (EST EST electroshock therapy. EST abbr. electroshock therapy ) at the New York Palace
New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Individuals may listen to a live web cast of these presentations by logging on to the Investor Relations section of Conceptus' web site www.conceptus.com a few minutes prior to start time to download any necessary software. About the Essure([R]) Procedure The Essure procedure, approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in 2002, deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal Tubal (t  `bəl), in the Bible, son of Japheth. access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80% effective (based on four years of follow-up data). The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74% effective (based on 5 years of follow-up data). Five-year follow-up of all patients in clinical trials is ongoing. About Conceptus Conceptus Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy vasectomy, male sterilization by surgical excision of the vas deferens, the thin duct that carries sperm cells from the testicles to the prostate and the penis. , which combined account for more than 1 million procedures annually. Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion